Your browser doesn't support javascript.
loading
Brain uptake and safety of Flutemetamol F 18 injection in Japanese subjects with probable Alzheimer's disease, subjects with amnestic mild cognitive impairment and healthy volunteers.
Miki, Takami; Shimada, Hiroyuki; Kim, Jae-Seung; Yamamoto, Yasuji; Sugino, Masakazu; Kowa, Hisatomo; Heurling, Kerstin; Zanette, Michelle; Sherwin, Paul F; Senda, Michio.
Afiliación
  • Miki T; Department of Geriatrics, Osaka City University Hospital, 5-7, Asahi-machi 1-chome, Abeno-ku, Osaka City, Japan. m1359432@med.osaka-cu.ac.jp.
  • Shimada H; Izumiotsu Municipal Hospital, Shimojyo-chou 16-1, Izumiotsu, Osaka, 595-0027, Japan. m1359432@med.osaka-cu.ac.jp.
  • Kim JS; Department of Geriatrics, Osaka City University Hospital, 5-7, Asahi-machi 1-chome, Abeno-ku, Osaka City, Japan.
  • Yamamoto Y; Nuclear Medicine Department, Asan Medical Center, 388-1 Pungnap-2 Dong, Songpa-Gu, Seoul, South Korea.
  • Sugino M; Neuropsychiatry Department, Kobe University Hospital, 5-2, Kusunoki-cho 7-chome, Chuo-ku, Kobe City, Hyogo Prefecture, Japan.
  • Kowa H; Aino Hospital, Center of Geriatric Somato-Psychological Care, 11-18, Takada-cho, Ibaraki City, Osaka, Japan.
  • Heurling K; Neurology Department, Kobe University Hospital, 5-2, Kusunoki-cho 7-chome, Chuo-ku, Kobe City, Hyogo Prefecture, Japan.
  • Zanette M; GE Healthcare, Uppsala, Sweden.
  • Sherwin PF; Nuclear Medicine and PET, Uppsala University, Uppsala, Sweden.
  • Senda M; GE Healthcare, Marlborough, MA, USA.
Ann Nucl Med ; 31(3): 260-272, 2017 Apr.
Article en En | MEDLINE | ID: mdl-28181118
ABSTRACT

OBJECTIVE:

This Phase 2 study assessed the performance of positron emission tomography (PET) brain images made with Flutemetamol F 18 Injection in detecting ß-amyloid neuritic plaques in Japanese subjects.

METHODS:

Seventy subjects (25 with probable Alzheimer's disease (pAD), 20 with amnestic mild cognitive impairment (aMCI), and 25 cognitively normal healthy volunteers[HVs]) underwent PET brain imaging after intravenous Flutemetamol F 18 Injection (185 MBq). Images were interpreted as normal or abnormal for neuritic plaque density by each of five non-Japanese and five Japanese readers who were blinded to clinical data. The primary efficacy analysis (based on HV and pAD data) was the agreement of the non-Japanese readers' image interpretations with the clinical diagnosis, resulting in estimates of positive percent agreement (PPA; based on AD subjects; similar to sensitivity) and negative percent agreement (NPA; based on HVs; similar to specificity). Secondary analyses included PPA and NPA for the Japanese readers; inter-reader agreement (IRA); intra-reader reproducibility (IRR); quantitative image interpretations (standardized uptake value ratios [SUVRs]) by diagnostic subgroup; test-retest variability in five pAD subjects; and safety.

RESULTS:

PPA was 92% for all non-Japanese readers and ranged from 88 to 92% for the Japanese readers. NPA ranged from 96 to 100% for both the non-Japanese readers and the Japanese readers. The majority image interpretations (the interpretations made independently by ≥3 of 5 readers) resulted in PPA values of 92 and 92% and NPA values of 100 and 96% for the non-Japanese and Japanese readers, respectively. IRA and IRR were strong. Composite SUVR values (mean of multiple regional values) allowed clear differentiation between pAD subjects and HVs. Test-retest variability ranged from 1.14 to 2.27%, and test-retest agreement of the blinded visual interpretations was 100% for all readers. Flutemetamol F 18 Injection was generally well tolerated.

CONCLUSIONS:

The detection of brain neuritic plaques in Japanese subjects using [18F]Flutemetamol PET images gave results highly consistent with clinical diagnosis, with non-Japanese and Japanese readers giving similar results. Inter-reader agreement and intra-reader reproducibility were high for both sets of readers. Visual delineation of abnormal and normal scans was corroborated by quantitative assessment, with low test-retest variability. TRIAL REGISTRATION Clinicaltrials.gov registration number NCT02813070.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Encéfalo / Tomografía de Emisión de Positrones / Benzotiazoles / Enfermedad de Alzheimer / Disfunción Cognitiva / Compuestos de Anilina Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Año: 2017 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Encéfalo / Tomografía de Emisión de Positrones / Benzotiazoles / Enfermedad de Alzheimer / Disfunción Cognitiva / Compuestos de Anilina Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Año: 2017 Tipo del documento: Article